The University of Texas Health Science Center at Houston: Research to Revenue

The University of Texas Health Science Center at Houston

Summit Venture Studio

Research to Revenue Report

Summit Venture Studio (SVS) Opportunities

SVS has identified 14 commercialization opportunities from The University of Texas Health Science Center at Houston and scored them based on our proprietary metrics and rubrics.

The SVS model is to identify the top 1% of commercialization opportunities and start companies around them.

Please connect with SVS if you would like to engage with us in our startup and investment efforts.

Return on Research (ROR) Analysis

Commercialization Revenue per Research Dollar

Top Universities by Return on Research (ROR)

ROI Ratio: Commercialization Revenue ÷ Research Funding

University Innovation Analysis

Total Innovation Scores by Institution

Top Universities by Innovation Score

180+ High Innovation

150-179 Strong Innovation

130-149 Moderate Innovation

100-129 Emerging Innovation

130+ total score considered high innovation impact

SVS Innovation Index

Proprietary Assessment of The University of Texas Health Science Center at Houston's Innovation Ecosystem
Score out of 100. Benchmark: Top 50 U.S. research institutions.
A score of 90/100 can be read "doing better than 90% of schools benchmarked"

Innovation Visibility

37/100

Definition: Media mentions, publication count, and global research visibility metrics

Startup Momentum

8/100

Definition: Growth in patents, funding, and startup formation

Ecosystem Strength

43/100

Definition: Tech transfer infrastructure and support systems

Innovation Legacy

A Timeline of Groundbreaking Discoveries

Innovation Timeline

Founded

1972

First Nobel

1996

First Patent

1975

First IPO

N/A

2022-2024

Cancer biomarker patent

2025

Today

Notable Commercialization Outcomes

Nobel Prizes

1984

Patent Milestone

First patent licensed

1984

Drug Development

Novel therapy commercialized

1999

Startup Launch

Spin-off company founded

2005

License Agreement

Major licensing deal

2012

Research Collaboration

Industry partnership formed

2017

Competitive Benchmarking

The University of Texas Health Science Center at Houston vs. Peer Research Universities

The University of Texas Health Science Center at Houston vs Peers Comparison

Metric	The University of Texas Health Science Center at Houston (FY2023)	Peer Average	Elite Average
Annual R&D Expenditure	$374M	$855M	$1,675M
New Inventions Disclosed	1	200	400
Startups Formed	2	7	10
Visibility Index	13	12	23
Licensing Revenue	$5M	$17M	$46M

Note: Peer Average = Median value among U.S. R1 research universities. Elite Average = Top 10 ranked U.S. research universities.

Emerging Opportunities

1. Precision Oncology Innovations Transforming Cancer Treatment Outcomes

Advanced genomic technologies enable personalized therapies, addressing cancer’s complexity and improving survival rates in a rapidly growing global oncology market.

2. AI-Driven Diagnostics Revolutionizing Early Disease Detection

Cutting-edge AI algorithms enhance diagnostic accuracy and speed, reducing healthcare costs and enabling scalable deployment across diverse medical institutions worldwide.

3. Regenerative Medicine Breakthroughs for Tissue Repair

Novel stem cell therapies offer scalable solutions for chronic injury repair, addressing significant unmet needs in aging populations and expanding global regenerative markets.

4. Novel Antimicrobial Agents Combatting Drug-Resistant Infections

Development of unique antimicrobials targets resistant pathogens, addressing critical public health threats and tapping into a high-demand pharmaceutical market segment.

5. Advanced Neurotechnology Platforms for Brain Disorder Treatment

Innovative neuromodulation devices provide scalable, non-invasive therapies for neurological diseases, meeting growing market demand for effective brain health solutions.

6. Wearable Health Monitoring Systems Enabling Real-Time Patient Care

Integrated biosensors support continuous health tracking, improving chronic disease management and enabling scalable telemedicine applications in expanding digital health markets.